Evidence map›Paper›PMID 33768542›Full record

ArticleClinical pharmacology and therapeutics2021

Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.

Yiwei Liu, Wenjian Yang, Colton A Smith, Cheng Cheng, Seth E Karol, Eric C Larsen, Naomi Winick, William L Carroll, Mignon L Loh, Elizabeth A Raetz and 10 more

Open access · greenAbstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 1 country.

Yiwei LiuDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Wenjian YangDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0002-7305-5649
Colton A SmithDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Cheng ChengDepartment of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Seth E KarolDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Eric C LarsenMaine Children's Cancer Program, Scarborough, Maine, USA.
Naomi WinickDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
William L CarrollDepartment of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.
Mignon L LohDepartment of Pediatrics, University of California School of Medicine, San Francisco, California, USA.
Elizabeth A RaetzDepartment of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.
Stephen P HungerDepartment of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Stuart S WinterChildren's Minnesota Cancer and Blood Disorders Program, Children's Minnesota, Minneapolis, Minnesota, USA.
Kimberly P DunsmoreDepartment of Pediatrics, University of Virginia, Charlottesville, Virginia, USA.
Meenakshi DevidasGlobal Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jun J YangDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
William E EvansDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Sima JehaDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ching-Hon PuiDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Hiroto InabaDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Mary V RellingDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
St. Jude Children's Research Hospital · USNew York University · USCenter for Cancer and Blood Disorders · USChildren's Hospital of Philadelphia · USNew England Cancer Specialists · USThe University of Texas Southwestern Medical Center · USUniversity of California, San Francisco · USUniversity of Virginia · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Glucocorticoids in Lymphoblastic LeukemiaR01CA142665 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2020
$4.6M
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA142665NIGMS NIH HHS P50 GM115279NIH HHS P50 115279NIH HHS R01 CA 142665
6 · The paper itself

Abstract

We conducted the first human leukocyte antigen (HLA) allele and genome-wide association study to identify loci associated with hypersensitivity reactions exclusively to the PEGylated preparation of asparaginase (pegaspargase) in racially diverse cohorts of pediatric leukemia patients: St Jude Children's Research Hospital's Total XVI (TXVI, n = 598) and Children's Oncology Group AALL0232 (n = 2,472) and AALL0434 (n = 1,189). Germline DNA was genotyped using arrays. Genetic variants not genotyped directly were imputed. HLA alleles were imputed using SNP2HLA or inferred using BWAkit. Analyses between genetic variants and hypersensitivity were performed in each cohort first using cohort-specific covariates and then combined using meta-analyses. Nongenetic risk factors included fewer intrathecal injections (P = 2.7 × 10

Indexed as

AllelesAsparaginaseCohort StudiesGene FrequencyGenome-Wide Association StudyGenotypeHaplotypesHistocompatibility Antigens Class IIHumansPolyethylene GlycolsPolymorphism, Single NucleotideAsparaginaseHistocompatibility Antigens Class IIpegaspargasePolyethylene Glycols

Identifiers

PMID33768542
PMCPMC8790808
OpenAlexW3138674172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.